The two companies are combining their technologies to speed the process of bringing to market treatments for Dengue fever and other diseases.
PolarisQB (based in Durham, NC) is working with Fujitsu (headquartered in Tokyo, Japan) to engineer a platform intended to speed the development of various drugs. The platform combines machine learning, hybrid quantum mechanics and molecular mechanics simulations (QM/MM).
According to the companies, the new platform makes it possible to achieve faster, more cost-eective discovery of novel lead molecules to develop new drugs. The rst joint project on tap using the platform: a drug discovery project targeting Dengue fever, a disease that currently has no approved treatments.
Shahar Keinan, PolarisQB CEO, told Outsourcing-Pharma the members of the partnership decided to begin their work on a serious, treatment-elusive condition.
“We have chosen the Dengue target because of the toll it creates on human health all over the world,” she said. “Also, the PolarisQB team have previously worked with a dierent Dengue target and we have identied a third party for the testing and further development of these leads.”
Dengue fever causes approximately 100 million infections and 22,000 deaths annually. The partnership companies estimate the new lead molecules for a Dengue fever drug are estimated will be available for next stages by May 2020.
According to the companies, researchers working under the existing drug delivery system involves identifying candidate molecules from a huge selection of options number of options that can bind to and block (or activate) the specic protein key to that disease.

Source: https://www.outsourcing-pharma.com/Article/2020/03/24/PolarisQB-Fujitsu-partner-on-drug-discovery